Duloxetine  ||| S:0 E:11 ||| NNP
in  ||| S:11 E:14 ||| IN
major  ||| S:14 E:20 ||| JJ
depressed  ||| S:20 E:30 ||| JJ
patients  ||| S:30 E:39 ||| NNS
resistant  ||| S:39 E:49 ||| VBP
to  ||| S:49 E:52 ||| TO
SSRIs  ||| S:52 E:58 ||| JJ
and ||| S:58 E:61 ||| CC
/ ||| S:61 E:62 ||| NNP
or  ||| S:62 E:65 ||| CC
venlafaxine  ||| S:65 E:77 ||| JJ
Several  ||| S:77 E:85 ||| JJ
acute  ||| S:85 E:91 ||| JJ
depression  ||| S:91 E:102 ||| NN
trials  ||| S:102 E:109 ||| NNS
suggest  ||| S:109 E:117 ||| VBP
that  ||| S:117 E:122 ||| IN
only  ||| S:122 E:127 ||| RB
35 ||| S:127 E:129 ||| CD
%  ||| S:129 E:131 ||| NN
of  ||| S:131 E:134 ||| IN
the  ||| S:134 E:138 ||| DT
patients  ||| S:138 E:147 ||| NNS
achieve  ||| S:147 E:155 ||| VBP
remission  ||| S:155 E:165 ||| JJ
state  ||| S:165 E:171 ||| NN
with  ||| S:171 E:176 ||| IN
antidepressant  ||| S:176 E:191 ||| JJ
monotherapy ||| S:191 E:202 ||| NN
.  ||| S:202 E:204 ||| .
An  ||| S:204 E:207 ||| DT
increasing  ||| S:207 E:218 ||| JJ
body  ||| S:218 E:223 ||| NN
of  ||| S:223 E:226 ||| IN
evidence  ||| S:226 E:235 ||| NN
is  ||| S:235 E:238 ||| VBZ
emerging  ||| S:238 E:247 ||| VBG
suggesting  ||| S:247 E:258 ||| VBG
that  ||| S:258 E:263 ||| IN
multi-action  ||| S:263 E:276 ||| JJ
antidepressants  ||| S:276 E:292 ||| NN
might  ||| S:292 E:298 ||| MD
be  ||| S:298 E:301 ||| VB
more  ||| S:301 E:306 ||| RBR
effective  ||| S:306 E:316 ||| JJ
in  ||| S:316 E:319 ||| IN
treatment-resistant  ||| S:319 E:339 ||| JJ
depressed  ||| S:339 E:349 ||| JJ
patients  ||| S:349 E:358 ||| NNS
than  ||| S:358 E:363 ||| IN
single-action  ||| S:363 E:377 ||| JJ
agents ||| S:377 E:383 ||| NNS
.  ||| S:383 E:385 ||| .
In  ||| S:385 E:388 ||| IN
this  ||| S:388 E:393 ||| DT
context ||| S:393 E:400 ||| NN
,  ||| S:400 E:402 ||| ,
the  ||| S:402 E:406 ||| DT
purpose  ||| S:406 E:414 ||| NN
of  ||| S:414 E:417 ||| IN
the  ||| S:417 E:421 ||| DT
study  ||| S:421 E:427 ||| NN
was  ||| S:427 E:431 ||| VBD
to  ||| S:431 E:434 ||| TO
assess  ||| S:434 E:441 ||| VB
the  ||| S:441 E:445 ||| DT
effectiveness  ||| S:445 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
duloxetine  ||| S:462 E:473 ||| NN
in  ||| S:473 E:476 ||| IN
treatment-resistant  ||| S:476 E:496 ||| JJ
major  ||| S:496 E:502 ||| JJ
depressed  ||| S:502 E:512 ||| JJ
outpatients ||| S:512 E:523 ||| NN
.  ||| S:523 E:525 ||| .
We  ||| S:525 E:528 ||| PRP
performed  ||| S:528 E:538 ||| VBD
a  ||| S:538 E:540 ||| DT
retrospective  ||| S:540 E:554 ||| JJ
study  ||| S:554 E:560 ||| NN
assessing  ||| S:560 E:570 ||| VBG
the  ||| S:570 E:574 ||| DT
efficacy  ||| S:574 E:583 ||| NN
of  ||| S:583 E:586 ||| IN
duloxetine  ||| S:586 E:597 ||| NN
in  ||| S:597 E:600 ||| IN
major  ||| S:600 E:606 ||| JJ
depressed  ||| S:606 E:616 ||| JJ
outpatients  ||| S:616 E:628 ||| NNS
who  ||| S:628 E:632 ||| WP
did  ||| S:632 E:636 ||| VBD
not  ||| S:636 E:640 ||| RB
achieve  ||| S:640 E:648 ||| VB
full  ||| S:648 E:653 ||| JJ
symptom  ||| S:653 E:661 ||| NN
remission  ||| S:661 E:671 ||| NNS
( ||| S:671 E:672 ||| -LRB-
CGI-S  ||| S:672 E:678 ||| NNP
( ||| S:678 E:679 ||| -LRB-
severity ||| S:679 E:687 ||| LS
)  ||| S:687 E:689 ||| -RRB-
> ||| S:689 E:690 ||| CD
=3 ||| S:690 E:692 ||| CD
)  ||| S:692 E:694 ||| -RRB-
after  ||| S:694 E:700 ||| IN
treatment  ||| S:700 E:710 ||| NN
of  ||| S:710 E:713 ||| IN
adequate  ||| S:713 E:722 ||| JJ
dose  ||| S:722 E:727 ||| NN
and  ||| S:727 E:731 ||| CC
duration  ||| S:731 E:740 ||| NN
( ||| S:740 E:741 ||| -LRB-
more  ||| S:741 E:746 ||| JJR
than  ||| S:746 E:751 ||| IN
8  ||| S:751 E:753 ||| CD
weeks ||| S:753 E:758 ||| NNS
)  ||| S:758 E:760 ||| -RRB-
with  ||| S:760 E:765 ||| IN
at  ||| S:765 E:768 ||| IN
least  ||| S:768 E:774 ||| JJS
either  ||| S:774 E:781 ||| RB
one  ||| S:781 E:785 ||| CD
SSRI  ||| S:785 E:790 ||| NNP
or  ||| S:790 E:793 ||| CC
the  ||| S:793 E:797 ||| DT
SNRI  ||| S:797 E:802 ||| NNP
venlafaxine ||| S:802 E:813 ||| NN
.  ||| S:813 E:815 ||| .
We  ||| S:815 E:818 ||| PRP
excluded  ||| S:818 E:827 ||| VBD
patients  ||| S:827 E:836 ||| NNS
with  ||| S:836 E:841 ||| IN
a  ||| S:841 E:843 ||| DT
severe  ||| S:843 E:850 ||| JJ
medical  ||| S:850 E:858 ||| JJ
illness  ||| S:858 E:866 ||| NN
and  ||| S:866 E:870 ||| CC
a  ||| S:870 E:872 ||| DT
personality  ||| S:872 E:884 ||| NN
disorder ||| S:884 E:892 ||| NN
.  ||| S:892 E:894 ||| .
CGI-S  ||| S:894 E:900 ||| NNP
was  ||| S:900 E:904 ||| VBD
used  ||| S:904 E:909 ||| VBN
as  ||| S:909 E:912 ||| IN
a  ||| S:912 E:914 ||| DT
measure  ||| S:914 E:922 ||| NN
of  ||| S:922 E:925 ||| IN
symptom  ||| S:925 E:933 ||| JJ
severity  ||| S:933 E:942 ||| NN
and  ||| S:942 E:946 ||| CC
administered  ||| S:946 E:959 ||| VBN
before  ||| S:959 E:966 ||| IN
the  ||| S:966 E:970 ||| DT
prescription  ||| S:970 E:983 ||| NN
of  ||| S:983 E:986 ||| IN
duloxetine  ||| S:986 E:997 ||| NN
and  ||| S:997 E:1001 ||| CC
6  ||| S:1001 E:1003 ||| CD
weeks  ||| S:1003 E:1009 ||| NNS
later ||| S:1009 E:1014 ||| RB
.  ||| S:1014 E:1016 ||| .
The  ||| S:1016 E:1020 ||| DT
sample  ||| S:1020 E:1027 ||| NN
included  ||| S:1027 E:1036 ||| VBD
29  ||| S:1036 E:1039 ||| CD
patients  ||| S:1039 E:1048 ||| NNS
( ||| S:1048 E:1049 ||| -LRB-
9  ||| S:1049 E:1051 ||| CD
M ||| S:1051 E:1052 ||| NNP
,  ||| S:1052 E:1054 ||| ,
20  ||| S:1054 E:1057 ||| CD
F ||| S:1057 E:1058 ||| NN
) ||| S:1058 E:1059 ||| -RRB-
.  ||| S:1059 E:1061 ||| .
We  ||| S:1061 E:1064 ||| PRP
observed  ||| S:1064 E:1073 ||| VBD
a  ||| S:1073 E:1075 ||| DT
very  ||| S:1075 E:1080 ||| RB
significant  ||| S:1080 E:1092 ||| JJ
decrease  ||| S:1092 E:1101 ||| NN
in  ||| S:1101 E:1104 ||| IN
CGI-S  ||| S:1104 E:1110 ||| JJ
scores  ||| S:1110 E:1117 ||| NNS
( ||| S:1117 E:1118 ||| -LRB-
4.86  ||| S:1118 E:1123 ||| CD
±  ||| S:1123 E:1125 ||| CD
0.51  ||| S:1125 E:1130 ||| CD
to  ||| S:1130 E:1133 ||| TO
2.17  ||| S:1133 E:1138 ||| CD
±  ||| S:1138 E:1140 ||| CD
1.44 ||| S:1140 E:1144 ||| CD
,  ||| S:1144 E:1146 ||| ,
p  ||| S:1146 E:1147 ||| CD
< ||| S:1147 E:1148 ||| SYM
0.0001 ||| S:1148 E:1154 ||| CD
)  ||| S:1154 E:1156 ||| -RRB-
after  ||| S:1156 E:1162 ||| IN
treatment  ||| S:1162 E:1172 ||| NN
with  ||| S:1172 E:1177 ||| IN
duloxetine  ||| S:1177 E:1188 ||| NNS
( ||| S:1188 E:1189 ||| -LRB-
dose  ||| S:1189 E:1194 ||| NN
between  ||| S:1194 E:1202 ||| IN
60  ||| S:1202 E:1205 ||| CD
and  ||| S:1205 E:1209 ||| CC
120  ||| S:1209 E:1213 ||| CD
mg ||| S:1213 E:1215 ||| CD
) ||| S:1215 E:1216 ||| -RRB-
.  ||| S:1216 E:1218 ||| .
Remission  ||| S:1218 E:1228 ||| NNP
was  ||| S:1228 E:1232 ||| VBD
achieved  ||| S:1232 E:1241 ||| VBN
in  ||| S:1241 E:1244 ||| IN
48 ||| S:1244 E:1246 ||| CD
%  ||| S:1246 E:1248 ||| NN
of  ||| S:1248 E:1251 ||| IN
the  ||| S:1251 E:1255 ||| DT
patients ||| S:1255 E:1263 ||| NNS
.  ||| S:1263 E:1265 ||| .
The  ||| S:1265 E:1269 ||| DT
tolerance  ||| S:1269 E:1279 ||| NN
was  ||| S:1279 E:1283 ||| VBD
excellent ||| S:1283 E:1292 ||| JJ
.  ||| S:1292 E:1294 ||| .
This  ||| S:1294 E:1299 ||| DT
study  ||| S:1299 E:1305 ||| NN
suggests  ||| S:1305 E:1314 ||| VBZ
the  ||| S:1314 E:1318 ||| DT
potential  ||| S:1318 E:1328 ||| JJ
interest  ||| S:1328 E:1337 ||| NN
of  ||| S:1337 E:1340 ||| IN
duloxetine  ||| S:1340 E:1351 ||| NN
in  ||| S:1351 E:1354 ||| IN
some  ||| S:1354 E:1359 ||| DT
treatment-resistant  ||| S:1359 E:1379 ||| JJ
depressed  ||| S:1379 E:1389 ||| JJ
patients ||| S:1389 E:1397 ||| NNS
.  ||| S:1397 E:1399 ||| .
